- Home
- MBX vs CHI Comparison
MBX vs CHI Comparison
Compare MBX & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBX
- CHI
- Stock Information
- Founded
- MBX 36
- CHI 2002
- Country
- MBX United States
- CHI United States
- Employees
- MBX N/A
- CHI N/A
- Industry
- MBX
- CHI Investment Managers
- Sector
- MBX
- CHI Finance
- Exchange
- MBX NYSE
- CHI Nasdaq
- Market Cap
- MBX 762.6M
- CHI 879.5M
- IPO Year
- MBX 2024
- CHI N/A
- Fundamental
- Price
- MBX $18.50
- CHI $12.08
- Analyst Decision
- MBX Strong Buy
- CHI
- Analyst Count
- MBX 4
- CHI 0
- Target Price
- MBX $37.25
- CHI N/A
- AVG Volume (30 Days)
- MBX 96.8K
- CHI 186.2K
- Earning Date
- MBX 11-07-2024
- CHI 01-01-0001
- Dividend Yield
- MBX N/A
- CHI 9.90%
- EPS Growth
- MBX N/A
- CHI N/A
- EPS
- MBX N/A
- CHI N/A
- Revenue
- MBX N/A
- CHI N/A
- Revenue This Year
- MBX N/A
- CHI N/A
- Revenue Next Year
- MBX N/A
- CHI N/A
- P/E Ratio
- MBX N/A
- CHI N/A
- Revenue Growth
- MBX N/A
- CHI N/A
- 52 Week Low
- MBX $15.31
- CHI $9.70
- 52 Week High
- MBX $27.50
- CHI $11.61
- Technical
- Relative Strength Index (RSI)
- MBX N/A
- CHI 59.96
- Support Level
- MBX N/A
- CHI $11.60
- Resistance Level
- MBX N/A
- CHI $12.08
- Average True Range (ATR)
- MBX 0.00
- CHI 0.17
- MACD
- MBX 0.00
- CHI 0.03
- Stochastic Oscillator
- MBX 0.00
- CHI 87.26
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.